University of Minnesota
Minneapolis, Minnesota, 55455, United States
Location status: Recruiting
NCT Number: NCT07109739
This study will assess the dose-response effects of Inspiratory Muscle Strength Training (IMST) in adults with above-normal systolic blood pressure over a 6-week period.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Minneapolis, Minnesota, 55455, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The POWERbreathe K5 is portable, battery-powered, and commercially available. No modifications to the FDA-approved design are being made. Its use in this study is consistent with prior published human research and does not constitute a significant deviation from labeled use in terms of safety or function.
Time frame: Week 6
To determine resting SBP before and after 6 weeks of IMST 15, IMST 30, or IMST 45 (75% PI max for all groups) in men and women aged ≥18 years with resting SBP ≥120 mmHg.
Contact information is provided by the study sponsor or research team.
University of Minnesota
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04755764
Cardiac Output, High, Cardiac Output, Low
Huntington, West Virginia, United States
View Trial DetailsNCT05086523
Cardiovascular Diseases, Essential Hypertension
Prague, Czechia
View Trial DetailsNCT03712033
Blood Pressure, High, Brain Diseases
Vancouver, British Columbia, Canada
View Trial DetailsNCT01281306
Cardiovascular Diseases, Essential Hypertension
Clearwater, Florida, United States
View Trial Details